Safi F, Beger H G, Bittner R, Büchler M, Krautzberger W
Cancer. 1986 Feb 15;57(4):779-83. doi: 10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c.
The diagnostic place value of CA 19-9, a tumor-associated antigen, was tested in 611 patients. This group of patients included 273 patients who suffered from a malignant disease (48 patients with pancreatic carcinomas and 225 patients with extrapancreatic malignant growths) and 338 patients with benign diseases (66 patients with chronic pancreatitis, 36 patients with acute pancreatitis, and 236 patients with general surgical diseases). In 93% of the patients with pancreatic carcinoma (media value, 528 U/ml), in 37% and 19% of the patients with carcinoma of the stomach and colorectal carcinomas (median value 8 U/ml), respectively, the CA 19-9 value was estimated as being above the normal limits of 6 to 37 U/ml. A sensitivity of 93% and a specificity of 85%, as well as a total accuracy of 82%, were established in pancreatic carcinoma during preoperative observation. The preoperatively raised CA 19-9 concentration in patients with pancreatic carcinomas dropped after curative resection of the carcinoma to within normal limits. However, a serum concentration of less than 37 U/ml was not recorded in any CA 19-9 estimation after a palliative surgical intervention, or in any case of inoperable carcinomas.
对611例患者检测了肿瘤相关抗原CA 19 - 9的诊断价值。该组患者包括273例患有恶性疾病的患者（48例胰腺癌患者和225例胰腺外恶性肿瘤患者）以及338例患有良性疾病的患者（66例慢性胰腺炎患者、36例急性胰腺炎患者和236例普通外科疾病患者）。93%的胰腺癌患者（中位值为528 U/ml）、37%的胃癌患者和19%的结直肠癌患者（中位值为8 U/ml）的CA 19 - 9值高于6至37 U/ml的正常范围。术前观察期间，胰腺癌的敏感性为93%，特异性为85%，总准确率为82%。胰腺癌患者术前升高的CA 19 - 9浓度在癌肿根治性切除后降至正常范围内。然而，在姑息性手术干预后的任何CA 19 - 9检测中，或在任何无法手术切除的癌肿病例中，均未记录到血清浓度低于37 U/ml的情况。
